A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with Type 2 Diabetes Mellitus and treated with metformin at a dose greater than or equal to 1000 mg for at least 3 months and are willing to switch to canagliflozin from metformin for the duration of the study
Hemoglobin A1c of 7-10% at screening.
Body Mass Index of at least 25 kg/m2.
You may not be if
Compliant with study drug administration during the run-in period and throughout the trial.
Patients with fasting triglycerides greater than 500 mg/dL at screening.
History of certain diabetic complications or cardiac problems.
Clareo Health | A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin
